GlassScriptPhysician profile
Mohammed S Seedat
NPI 1679683031
$11,407.56
in general payments reported to CMS, 2019-2025
41 companies · $1,645 in 2025
The $1,645 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,883 · 2020: $1,216 · 2021: $1,837 · 2022: $1,795 · 2023: $1,822 · 2024: $1,210 · 2025: $1,645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,427 · Education: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,427.42 |
| Education | $249.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,095.98 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Grifols USA, LLC | $1,224.45 | 2019-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,208.76 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $1,095.04 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Electromed, INC. | $997.07 | 2019-2025 | Smartvest |
| Mylan Specialty L.P. | $650.15 | 2019-2024 | Yupelri |
| Insmed, INC. | $393.52 | 2019-2025 | Arikayce |
| Philips North America LLC | $331.94 | 2019-2024 | (Ak6) Vest Therapy |
| Jazz Pharmaceuticals INC. | $309.04 | 2019-2025 | |
| Genzyme Corporation | $292.92 | 2019-2025 | |
| Harmony Biosciences LLC | $265.95 | 2023-2025 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $232.29 | 2021-2025 | Glassia |
| Janssen Pharmaceuticals, INC | $215.90 | 2019-2023 | Xarelto |
| Pfizer INC. | $203.90 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $172.88 | 2019-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $160.38 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $159.35 | 2021-2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $142.28 | 2020-2024 | Austedo Xr |
| Verona Pharma, INC. | $137.81 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $134.91 | 2023-2025 | Uptravi, Opsumit |
| Baxter Healthcare | $116.77 | 2023 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Paratek Pharmaceuticals, INC. | $94.09 | 2019-2021 | |
| Genentech USA, INC. | $85.60 | 2019 | |
| Sk Life Science, INC. | $85.44 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $74.35 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $67.99 | 2025 | |
| Lilly USA, LLC | $67.39 | 2025 | Zepbound, Mounjaro |
| Neurocrine Biosciences, INC. | $58.34 | 2023-2024 | Ingrezza, Ongentys |
| Mallinckrodt Enterprises LLC | $45.05 | 2019 | |
| Acorda Therapeutics, INC | $42.17 | 2023 | Ampyra, Inbrija |
| Inogen, INC. | $41.70 | 2024 | |
| Merck Sharp & Dohme LLC | $32.71 | 2021-2023 | |
| Pulmonx Corporation | $23.49 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Csl Behring | $23.38 | 2021 | |
| United Therapeutics Corporation | $20.58 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.80 | 2019 | |
| Advanced Respiratory, INC | $19.55 | 2019 | |
| Ambu INC. | $18.48 | 2025 | |
| Nestle Healthcare Nutrition INC. | $17.88 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.75 | 2022 | |
| Nabriva Therapeutics, Plc | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Seedat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.